Treatment Considerations in MDS from ASCO/EHA 2022
Treatment Considerations in MDS from ASCO/EHA 2022
MDS Foundation
The Evolving Use of Immune Checkpoint Blockade in Management of MDS
FEATURING
Amer Zeidan
- 191 views
- April 20, 2022
- 2
Penn Medicine Abramson Cancer Center
Highlights in the Prognostication of MDS This Year
FEATURING
Shannon McCurdy
- 34 views
- May 4, 2022
Yale Cancer Center
The Importance of the TP53 Evaluation in the Management of HR-MDS
FEATURING
Rory Shallis
- 40 views
- July 15, 2022
Penn Medicine Abramson Cancer Center
EHA and ASCO 2022 Penn Medicine Updates on AML and MDS
FEATURING
Keith Pratz
- 255 views
- July 15, 2022
SOHO Italy 1st Clinical and Biological School of CAR-T
T, NK, and Macrophage-Based Therapies in AML
FEATURING
Naval Daver
- 194 views
- May 2, 2022
- 1
MDS Foundation
Making Heads and Tails of NGS Printouts and Their Role in MDS
FEATURING
Benjamin Ebert
- 56 views
- April 26, 2022
MDS Foundation
Mechanisms and Predictors of Drug Resistance in HR-MDS: Intolerance to HMAs and Clinical Management Strategies
FEATURING
Mikkael Sekeres
- 18 views
- April 26, 2022
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
2022 State of the Art Frontline Management of the HR-MDS
FEATURING
Rami Komrokji
- 339 views
- February 14, 2022
- 2
EHA 2022 Conference Coverage
EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magrolimab
FEATURING
David Sallman
- 391 views
- August 4, 2022
EHA 2022 Conference Coverage
Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magrolimab
FEATURING
David Sallman
- 15 views
- August 4, 2022
MDS Foundation
Optimizing Transfusion Support for Patients With MDS
FEATURING
Yulia Lin
- 42 views
- April 26, 2022